# Fragile Conclusion Review 001

Objective: stress-test the most fragile conclusions produced tonight.

Scope: existing Research Journal and AEGIS diagnostic review evidence only. This review adds no architecture, schemas, systems, runtime truth changes, trading logic, trade advice, candidates, or allocation authority.

Inputs:
- `journal_review_001.md`
- `journal_review_002.md`
- `root_cause_review_001.md`
- `outcome_maturity_acceleration_review_001.md`
- `aegis_misdiagnosis_review_001.md`

## 1. Low Candidate Production Is Not Primarily Sleeve Weakness

Confidence level: MEDIUM.

Strongest supporting evidence:

- Sleeve throughput diagnostics for 2026-06-03 showed 5 FLOWING sleeves, 4 DORMANT sleeves, 1 BLOCKED sleeve, and 0 UNDERPRODUCING sleeves.
- Sleeve throughput evidence classification showed 5 FLOWING, 4 HEALTHY_NO_CANDIDATE, 1 NEEDS_DATA, 0 NEEDS_REPAIR, and 0 NEEDS_GOVERNANCE.
- Dormant-sleeve diagnostics found valid no-signal conditions, trigger thresholds not met, optional simulator filtering, and one data/runtime issue rather than broad sleeve-quality failure.
- Candidate diagnostics showed low generated-candidate output was partly explained by expected portfolio-gate suppression and certification state, not only by sleeve logic.

Strongest contradictory evidence:

- Some hypotheses still have no candidate flow, no observation flow, no paper path, implementation incomplete status, or REDESIGN classifications.
- `C2_EVENT_DISLOCATION_V1` exposed a data/runtime path issue rather than clean healthy selectivity.
- Four evaluated sleeves had paper activity but 0 closed evidence-certification samples.
- Current evidence rejects a broad weak-sleeve diagnosis, but it does not prove sleeve quality.

What future evidence would change the conclusion:

- Repeated cycles where HEALTHY_NO_CANDIDATE sleeves fail to generate candidates despite favorable, threshold-satisfying conditions.
- Evidence that no-signal or threshold rules are too restrictive, stale, or badly calibrated.
- Data and paper-path repairs followed by continued failure to produce candidates or usable outcomes.
- Closed-outcome samples showing low-producing sleeves consistently perform poorly once measurable.

Estimated roadmap impact if wrong: HIGH.

If low candidate production is actually sleeve weakness, the current roadmap could over-prioritize outcome follow-through and under-prioritize sleeve redesign, trigger calibration, implementation repair, and paper-path reconstruction. AEGIS would wait for outcomes from sleeves that are structurally unlikely to produce useful evidence.

## 2. Outcome Maturity Is The Primary Bottleneck

Confidence level: HIGH, with an upstream-cause caveat.

Strongest supporting evidence:

- On 2026-06-03, AEGIS had 63 paper positions, 51 open positions, 12 closed positions, and 12 included validation samples.
- Research quality showed 10 hypotheses, 6 underpowered, 4 blocked, and 0 ready for capital review.
- Statistical sufficiency showed 9 hypotheses, 8 underpowered, 1 validation-ready, and 0 validated.
- Sleeve evidence certification showed all 5 evaluated sleeves UNDERPOWERED, with 1 BUILDING_SAMPLE and 4 ZERO_SAMPLE.
- Outcome Maturity Acceleration Review 001 identified existing paper-position follow-through as the highest-leverage near-term path.

Strongest contradictory evidence:

- Root Cause Review 001 found 42 raw signals produced only 1 generated candidate and 1 paper position.
- Several hypotheses remain blocked by implementation, paper-path, candidate-flow, observation-flow, or data-source gaps before outcome maturity can be tested.
- The open-position follow-through review found all 51 reviewed open positions remained `HOLD`, and 47 of 51 were not near deterministic closure.
- Misdiagnosis Review 001 found outcome maturity may be the visible downstream bottleneck while candidate-to-paper conversion and measurable-flow generation may be deeper causes.

What future evidence would change the conclusion:

- Evidence that closed outcomes accumulate but remain uninformative because candidate quality, paper-path design, data authority, or validation structure is defective.
- Evidence that most existing open paper positions cannot create material validation maturity under deterministic closure rules.
- A future root-cause review showing candidate conversion, data readiness, or implementation repair blocks more learning than closed-sample scarcity.
- Multiple sleeves reaching closed-sample thresholds while still producing no reusable research conclusions.

Estimated roadmap impact if wrong: HIGH.

If outcome maturity is not the primary bottleneck, the roadmap could spend too much effort waiting for deterministic closures and too little effort on creating measurable candidate flow. This would delay learning and leave upstream defects unresolved.

## 3. Candidate Volume Is A Poor Proxy For Quality

Confidence level: HIGH.

Strongest supporting evidence:

- Candidate diagnostics showed 42 raw signals but only 1 generated candidate and 1 valid candidate contract.
- Detailed diagnostics showed most same-day raw-signal rejections were expected portfolio-gate suppressions, not direct evidence of candidate weakness.
- `HYP_EVENT_DISLOCATION_REPRICING_V1` had 23 candidates but 0 paper positions and 0 usable validation samples.
- Sleeve evidence certification showed all evaluated sleeves UNDERPOWERED despite candidate and paper-trade inventories.

Strongest contradictory evidence:

- `C2_TREND_EQ_PRIMARY_V1` had the largest candidate and paper-position inventory and is also the only meaningful closed-sample evidence source.
- Candidate and paper-position volume may be necessary for outcome accumulation even when it is not sufficient for quality.
- Low-volume sleeves have not produced enough closed samples to disprove a stage-specific relationship between throughput and learning value.

What future evidence would change the conclusion:

- Cross-sleeve evidence showing higher candidate volume consistently predicts valid contracts, paper positions, closed validation samples, and positive evidence after certification and governance effects are controlled.
- Repeated evidence that low-volume sleeves remain low-learning and high-volume sleeves improve validation quality.
- A conversion-quality model showing raw candidate volume is a reliable early signal once expected suppression and certification defects are removed.

Estimated roadmap impact if wrong: MEDIUM-HIGH.

If candidate volume is more informative than current reviews conclude, the roadmap may underweight high-throughput discovery surfaces and overcomplicate candidate interpretation. The risk is less severe than false capital readiness, but it would slow evidence accumulation.

## 4. Research Attention Allocation Is More Useful Than Capital Allocation

Confidence level: HIGH.

Strongest supporting evidence:

- Research quality, hypothesis decision policy, and research allocation recommendation artifacts showed 0 capital-review-ready rows.
- Capital authority readiness kept capital allocation and broker execution disallowed.
- Research attention artifacts produced differentiated read-only decisions, including hold, pause, decrease, redesign, needs-data, investigate-more, and research-attention-only program recommendations.
- Evidence remained underpowered and concentrated: 12 usable validation samples, all from one hypothesis and sleeve, with 0 validated hypotheses.

Strongest contradictory evidence:

- Research capital allocation artifacts already produce program-level research attention decisions, so naming can blur the line between research triage and capital allocation.
- `HYP_LARGE_CAP_EQUITY_MOMENTUM_20_60D_V1` reached validation-ready state at the statistical-sufficiency layer, which could be mistaken for capital-review proximity.
- Capital-review-style analysis may still help organize research priorities if it remains explicitly read-only and non-trading.

What future evidence would change the conclusion:

- Existing artifacts emit at least one hypothesis or sleeve as READY_FOR_CAPITAL_REVIEW or CAPITAL_REVIEW with sufficient, positive, distributed, closed-outcome evidence.
- Capital-review analysis produces better research outcomes without implying sizing, execution, or trading authority.
- Runtime truth and policy gates change to allow capital allocation only after mature validation evidence exists.

Estimated roadmap impact if wrong: VERY HIGH.

If capital allocation becomes useful earlier than recognized, AEGIS could miss a chance to translate validated evidence into disciplined review. If the conclusion is wrong in the opposite direction, and capital framing is allowed too early, the impact is worse: false confidence, premature allocation logic, and accidental pressure toward trade advice.

## 5. Technical Indicator Claims Are Weak

Confidence level: MEDIUM-HIGH for broad standalone claims; MEDIUM for all technical evidence.

Strongest supporting evidence:

- Technical Strategy Factory reviews found broad or standalone technical claims unsupported, false-positive-prone, baseline-recoverable, or non-generalizing.
- Evidence Test v2 had 62 blocked evidence items and 0 supported evidence items.
- Out-of-fixture non-naive rebenchmark found 0 qualified research asset candidates and 0 unique supported evidence count.
- Journal Review 001 concluded technical evidence must be relationship-specific and split by evidence type.

Strongest contradictory evidence:

- Some real-data technical patterns and controlled fixture candidates existed.
- Repaired-feature and non-naive tests improved question productivity and produced in-fixture support.
- `C2_TREND_EQ_PRIMARY_V1` is momentum-adjacent and is the only meaningful closed-sample evidence stream, even though early realized evidence is weak.
- Context-linked, mechanism-specific, or regime-specific technical structures have not been fully tested out of fixture.

What future evidence would change the conclusion:

- Out-of-fixture, baseline-adjusted, relationship-specific technical tests produce durable support.
- Closed-outcome evidence shows technical structures improve discovery quality, validation samples, or benchmark-relative results without hindsight dependence.
- Technical claims survive false-positive controls, regime controls, sample-independence checks, and competing-baseline tests.

Estimated roadmap impact if wrong: MEDIUM.

If technical indicator claims are stronger than current evidence suggests, AEGIS may underinvest in useful technical discovery surfaces. The current risk is moderated because the review does not reject all technical evidence; it rejects broad standalone claims and requires relationship-specific validation.

## Ranking

Most fragile:

1. Low candidate production is not primarily sleeve weakness.
2. Technical indicator claims are weak.
3. Outcome maturity is the primary bottleneck.
4. Candidate volume is a poor proxy for quality.
5. Research attention allocation is more useful than capital allocation.

Most dangerous if wrong:

1. Research attention allocation is more useful than capital allocation.
2. Outcome maturity is the primary bottleneck.
3. Low candidate production is not primarily sleeve weakness.
4. Candidate volume is a poor proxy for quality.
5. Technical indicator claims are weak.

Most robust:

1. Research attention allocation is more useful than capital allocation.
2. Candidate volume is a poor proxy for quality.
3. Outcome maturity is the primary bottleneck.
4. Technical indicator claims are weak.
5. Low candidate production is not primarily sleeve weakness.

## Overall Judgment

The most fragile conclusion remains the sleeve-weakness conclusion because current evidence rejects a broad weak-sleeve diagnosis but does not prove sleeve health. The most dangerous conclusion to get wrong is capital allocation versus research attention allocation because premature capital framing can create false confidence even without changing runtime authority. The most robust conclusion is that research attention is currently more useful than capital allocation, because all reviewed capital-readiness surfaces remain at 0 eligible rows while research triage has differentiated read-only value.
